Claudin 18.2 in cancer research and treatment: a pathologist’s perspective
Claudin 18.2 is a biologically plausible and clinically actionable biomarker. Robust pre-analytical handling, validated IHC protocols and standardised scoring are essential for reliable patient selection. Wider adoption of harmonised methods and further disease-specific studies will refine cut-offs, clarify prognostic value and optimise integration of Claudin 18.2-directed therapies into routine care.
Authors
- Vikram Deshpande (ORCID: https://orcid.org/0000-0003-4230-9308)
- Matteo Fassan (ORCID: https://orcid.org/0000-0001-6515-5482)
- Angela Baldwin
- Gurzhikhan Murtazaalieva (ORCID: https://orcid.org/0009-0009-4492-9237)
Institutions
- Beth Israel Deaconess Medical Center (US)
- Harvard University (US)
- University of Padua (IT)
- Rolls-Royce (United States) (US)
Publication Details
- Journal
- Journal of Clinical Pathology
- Published
- 2025-12-17
- DOI
- https://doi.org/10.1136/jcp-2025-210328
- Primary Topic
- Barrier Structure and Function Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00